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ABCB1-C3435T and breast cancer risk
Purpose: To investigate the association of ABCB1-C3435T 
transition with breast cancer risk which was followed by a 
meta-analysis.
Methods: In a case-control study we collected blood sam-
ples from 290 women (including 150 breast cancer patients 
and 140 healthy controls). ABCB1-C3435T genotyping 
was performed by polymerase chain reaction-restriction 
fragment length polymorphism (PCR-RFLP) method. A me-
ta-analysis was performed for a total of 13 eligible studies 
involving 5,835 cases and 8,178 controls.
Results: The results of case-control study revealed a signifi-
cant association between T allele (OR=1.770, 95%CI=1.236-
2.535, p=0.002), CT genotype (OR=1.661, 95%CI=1.017-
2.713, p=0.042), and TT genotype (OR=3.399, 95%CI=1.409-
8.197, p=0.006) with breast cancer risk. Data from me-
ta-analysis revealed a significant association between 
ABCB1-C3435T polymorphism and breast cancer risk in 
allelic (OR=1.243, 95%CI=1.079-1.432, p=0.003), co-domi-
nant (OR=1.349, 95%CI=1.042-1.746, p=0.023), dominant 
(OR=1.204, 95%CI=1.019-1.422, p=0.029), and recessive 
(OR=1.226, 95%CI=1.011-1.488, p=0.039) models.
Conclusions: The results suggest that the ABCB1-C3435T 
gene polymorphism might be a genetic risk factor and a 
potential biomarker for breast cancer.
Key words: ABCB1 gene, breast cancer, genetic polymor-
phism, meta-analysis
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Breast cancer is most widespread malignant 
disease in females worldwide [1]. In the last de-
cades, extensive progress has taken place in the 
diagnosis and therapy of breast cancer. Some ef-
forts were realized to identify environmental and 
genetic risk factors that contribute to the develop-
ment of breast cancer [2,3]. Complex interactions 
between genes (including BRCA1, BRCA2, PTEN, 
and p53) and epigenetic modifications (such as 
DNA methylation, chromatin remodeling), con-
tribute to breast cancer genesis. Genetic polymor-
phisms are a helpful tool to identify susceptibility 
genes as prognostic biomarkers [4]. Furthermore, 
some studies revealed that genetic variants of 
the adenosine triphosphate-binding cassette B1 
(ABCB1) gene, are associated with cancer suscep-
tibility [5,6].
ABCB1, also known as P-glycoprotein (P-gp), 
is encoded by MDR1 (multi-drug resistance) gene, 
and it is one of the most broadly studied ATP-bind-
ing membrane transporters. This molecule is 
an ATP-dependent drug efflux pump for a range 
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of carcinogens and antineoplastic agents, and it 
plays an important role in the defense against ex-
ogenous and endogenous toxins [7,8]. The ABCB1 
gene is located on chromosome 7 (7q21.1). Sin-
gle-nucleotide polymorphisms (SNPs) may re-
duce the function of ABCB1. There are more than 
50 variants in the ABCB1 gene. C3435T transition 
(with ID: rs1045642) which is located in exon 26 
is one of the most common polymorphisms in 
ABCB1 gene [9]. 
The aim of this study was to investigate the 
association of ABCB1-C3435T polymorphism with 
risk of breast cancer development, followed by a 
meta-analysis.
 
Methods
Subjects
Blood samples of 150 Iranian women with spo-
radic breast cancer were collected from the Shahid Be-
heshti Hospital (the first Affiliated Hospital of Kashan 
University of Medical Sciences, Kashan, Iran). The 
cases were diagnosed by clinical tests as well as mam-
mographic and pathological studies. We excluded pa-
tients with previous cancer and previous chemotherapy 
or radiotherapy. Blood samples from 140 age-matched 
healthy women (controls) from the same geographical 
area without history of familial malignancies were col-
lected. All the participants provided written informed 
consent and this study complied with the principles 
outlined in the Declaration of Helsinki and approved 
by the Hospital’s Ethics Committee.
SNP genotyping
Genomic DNA for genotype analyses was isolated 
from blood samples, using a DNGplus Kit (Cinnagen, 
Iran). For PCR, the entire genome sequence of ABCB1 
gene was deduced from NCBI database. The oligonu-
cleotide primers for ABCB1 gene containing C3435T 
transition were designed by oligo7 software (http://
www.oligo.net/). The sequences of forward and reverse 
primers were F: 5’- GTGAACTCTTGTTTTCAGCTG-3’ 
and R: 5’-CTTACATTAGGCAGTGACTCG-3’, respec-
tively. ABCB1-C3435T genotyping was done by poly-
merase chain reaction-restriction fragment length 
(PCR-RFLP). ABCB1 fragment was amplified with the 
use of 0.35 µM of each forward and reverse primers, 
0.5 µl dNTPs mix, and 1.5 µM MgCl2, Taq polymerase 
and template DNA in a total volume (all PCR reagents) 
were purchased from Fermentas Co., Germany. PCR 
was carried out in Eppendorf thermal cycler (Eppen-
dorf, Germany) with the following program: initial de-
naturation at 94°C for 5 min, 35 repetitive cycles of 30 
sec at 94°C, 30 sec at 53°C, 45 sec at 72°C, and final 
extension at 72°C for 5 min. 
PCR products were digested by Sau3AI at 37°C 
for 16 hrs, and then the enzyme mixture was electro-
phoresed onto 8% polyacrylamide gels and visualized 
by silver nitrate (AgNO3) staining. The digested sam-
ples presented 3 altered patterns: CC genotype, repre-
senting 167 and 33-bp fragments; TT genotype with 
230-bp fragments; and CT genotype with 230,167, and 
33-bp fragments.
Statistics
Hardy-Weinberg equilibrium (HWE) for both the 
cases and controls was calculated. The frequencies of 
alleles and genotypes were calculated by direct count-
ing. Comparisons of the alleles and genotypes frequen-
cies were assessed using the chi-square test. The asso-
ciations of each genotypes and alleles with breast can-
cer risk were estimated by odds ratios (ORs) and 95% 
confidence intervals (CIs). A two-tailed p value <0.05 
was considered as a statistically significant difference. 
Meta-analysis
We tried to detect all studies that investigated 
the association of ABCB1-C3435T polymorphism with 
breast cancer. To find related studies, we carried out 
a comprehensive systematic search through PubMed, 
ScienceDirect, Google Scholar, and other databas-
es on Sep 2015. The following words were searched: 
“ABCB1”, “MDR1”, “polymorphism”, “rs1045642”, and 
“breast cancer”. Moreover, some studies were recog-
nized by a manual exploration of the reference lists in 
the main articles. Of the studies with overlapping or 
similar data from the same researchers, the complete 
or most recent articles were included. Included studies 
had to satisfy the following criteria: (i) studies on hu-
mans; (ii) investigation of the ABCB1-C3435T polymor-
phism and breast cancer risk; (iii) case-control study 
design; (iv) HWE equilibrium should be established in 
control groups; (v) valid data were accessible to esti-
mate the odds ratio (OR) and its 95%CI.
Two of the authors extracted the data independent-
ly according to the aforementioned inclusion criteria. 
Inconsistencies around inclusion of articles and expla-
nation of data were decided by discussion and negotia-
tion with a specialist. The following data were extracted 
from each study: the first author’s name, year of publi-
cation, subject ethnicity, number of cases and controls, 
genotype frequency, and genotyping method. Different 
ethnicity was classified as Asian and Caucasian.
Chi-square test was used to assess the HWE in 
the control groups. The groups that deviated from the 
HWE had a p value <0.05. The strength of the associ-
ations between ABCB1-C3435T and breast cancer risk 
was evaluated by OR and 95%CI. Meta-analysis was 
carried out by the 5 following models: (1) T vs C al-
lele (allelic model), (2) TT vs CC genotype (co-dominant 
model), (3) CT vs CC genotype (co-dominant model), (4) 
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TT+CT genotype vs CC genotype (dominant model), 
and (5) TT vs CT+CC (recessive model). The heteroge-
neity test was done by the Q test and estimated I2 score 
[10], and p<0.1 was considered as a significant differ-
ence. When the p value of the Q test was >0.1, the fixed 
model was used [11], otherwise the random model was 
used [12]. Sensitivity analysis was done to evaluate the 
stability of meta-analysis by excluding an individual 
study each time. The Begg’s funnel plot and Egger’s 
test were used to assess the possible publication bias 
and p<0.05 was considered as presence of such bias 
[13,14]. OpenMeta[Analyst] (http://www.cebm.brown.
edu/open_meta/download) and Comprehensive Meta 
Analysis ver.2 software (http://www.meta-analysis.
com/index.php) were used to perform the statistical 
analysis.
Results 
Distribution of ABCB1-C3435T alleles and genotypes 
The ABCB1 genotypes distribution for C3435T 
transition was in HWE in the case and control 
groups. The alleles and genotypes frequencies for 
the C3435T in case and control groups are provid-
ed in Table 1. The frequencies of 3435CC, 3435CT, 
and 3435TT genotypes in the breast cancer group 
were 40.67, 45.33 and 14.00%, while these ra-
tios in the control group were 56.43, 37.86 and 
05.71%, respectively. The 3435C and 3435T al-
lele frequencies in the case group were 63.33 and 
36.67%, while these ratios in the control group 
were 75.36 and 24.64%, respectively. Genotype 
analysis revealed that there were significant as-
sociations between CT (OR=1.661, 95%CI=1.017-
2.713, p=0.042) and TT (OR=3.399, 95%CI=1.409-
8.197, p=0.006) genotypes and breast cancer risk. 
Furthermore, carriers of T allele (CT+TT) showed 
Table 1. Genotype and allele frequencies of ABCB1-C3435T 
in cases and controls
Genotype
No. and percentage OR
(95% CI)
n (%)
p valueControl
(n=140)
n (%)
Case  
(n=150)
n (%)
CC 79(56.43)
61
(40.67) - -
CT 53(37.86)
68
(45.33)
1.661
(1.017-
2.713)
0.042
TT 8(05.71)
21
(14.00)
3.399
(1.409-
8.197)
0.006
CT+TT 61(43.57)
89
(59.33)
1.889
(1.185-
3.013)
0.008
Allele
C 211(75.36)
190
(63.33) - -
T 69(24.64)
110
(36.67)
1.770
(1.236-
2.535)
0.002
OR: odds ratio, CI: confidence interval
Table 2. Characteristics of included studies
Country
(ethnicity)
Genotype frequencies
PHWE Genotypingmethod Author [Reference]Controls Cases
CC CT TT CC CT TT
Turkey 18 23 9 7 33 17 0.73 PCR–RFLP Turgut et al.  2007 [5]
Norway 40 17 52 33 9 51 <0.01 PCR-RFLP Nordgard et al. 2007 [15]
Spain 85 162 54 35 70 30 0.13 PCR–RFLP Henríquez-Hernández et al. 2009 [16]
Iran 12 45 20 16 57 33 0.11 PCR–RFLP Tatari et al. 2009 [17]
India 15 32 21 8 39 39 0.67 PCR–RFLP George et al. 2009 [18]
Iran 10 27 13 10 30 14 0.55 PCR–RFLP Taheri  et al. 2010 [19]
Slovak 35 54 24 46 108 67 0.71 PCR–RFLP Cizmarikova et al. 2010 [20]
Germany 1228 2736 1522 730 1543 902 0.98 MALDI-TOF MS Abbas et al. 2010 [21]
Poland 52 103 50 48 96 65 0.94 PCR–RFLP Rubiś et al. 2012 [22]
China 440 624 180 388 565 220 0.08 PCR–RFLP Wu et al. 2012 [23]
Mexico   37 103 43 32 83 13 0.09 PCR–RFLP Macías-Gómez et al. 2014 [24]
Mexico 56 72 24 82 133 33 0.92 PCR–RFLP Gutierrez-Rubio et al. 2015 [9]
Iran 79 53 8 61 68 21 0.82 PCR-RFLP This study
HWE:Hardy–Weinberg equilibrium, PCR:polymerase chain reaction, RFLP:restriction fragment length polymorphism. A Hardy–Wein-
berg equilibrium in the control group with p value <0.05 did not satisfy the Hardy–Weinberg equilibrium.
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most significant association with breast cancer 
risk (OR=1.889, 95%CI=1.185-3.013, p=0.008). Also, 
allele analysis showed a significant association be-
tween 3435T allele and breast cancer risk (OR=1.770, 
95%CI=1.236-2.535, p=0.002).
Meta-analysis
According to inclusion criteria a total of 12 
eligible articles were included in the meta-analy-
sis [5,9,15-24]. Also the data from our study were 
added to the meta-analysis. A flow chart present-
ing the study selection procedure is shown in Fig-
ure 1. As a result, 13 studies were included in the 
meta-analysis with 5,835 cases and 8,178 healthy 
controls. Table 2 shows the main features of all 
studies of the meta-analysis. There were 6 studies 
with Caucasians, 5 with Asians and 2 with Lati-
nos. One study applied MALDI-TOF MS to SNP 
genotyping whereas the others applied PCR-RFLP.
The overall results of the meta-analysis 
are summarized in Table 3. Overall, for the 13 
pooled studies, a significant association be-
tween ABCB1-C3435T and breast cancer was ob-
served in T vs C (OR=1.243, 95%CI=1.079-1.432, 
p=0.003), TT vs CC (OR=1.349, 95%CI=1.042-1.746, 
p=0.023), CT+TT vs CC (OR=1.204, 95%CI=1.019-
1.422, p=0.029), and TT vs CC+CT (OR=1.226, 
95%CI=1.011-1.488, p=0.039) models (Figure 2). 
Results of meta-analysis in Asian and Caucasian 
Table 3. Association results in the meta-analysis
Group
T vs C TT vs CC CT vs CC CT+TT vs CC TT vs CC+CT
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
OR
(95% CI) P
Total  1.24 (1.08- 1.43) 0.003
1.35 
(1.04- 1.75) 0.023
1.02 
(0.94- 1.11) 0.615
1.20 
(1.02- 1.42) 0.029
1.23 
(1.01- 1.49) 0.039
Asian  1.54 (1.11-2.13) 0.010
1.51 
(1.22- 1.87) < 0.001
1.10 
(0.94- 1.30) 0.222
1.20 
(1.03- 1.39) 0.018
1.42 
(1.18- 1.71) < 0.001
Caucasian 1.21(1.01- 1.45) 0.035
1.42 
(1.01- 2.00) 0.047
1.11 
(0.84- 1.47) 0.462
1.24 
(0.93- 1.64) 0.139
1.08 
(0.99- 1.19) 0.082
OR: odds ratio, CI: confidence interval
Figure 1. Study identification diagram.
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Figure 2. Forest plot for association of ABCB1-C3435T with breast cancer risk in overall meta-analysis. A) T vs C 
model; B) TT vs CC model; C) CT+TT vs CC model; D) TT vs CC+CT model.
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subgroups are summarized in Table 3. The results 
revealed that the ABCB1-C3435T was associated 
with breast cancer risk in Asian population in T vs C 
(OR=1.535, 95%CI=1.107-2.128, p=0.010), TT vs CC 
(OR=1.512, 95%CI=1.221-1.872, p<0.001), CT+TT 
vs CC (OR=1.199, 95%CI=1.031-1.394, p=0.018), 
and TT vs CC+CT (OR=1.422, 95%CI=1.181-1.712, 
p<0.001) models (Figure 3). Also, we observed a 
significant association between ABCB1-C3435T 
and breast cancer risk in Caucasian population in T 
vs C (OR=1.214, 95%CI=1.014-1.454, p=0.035) and 
TT vs CC (OR=1.419, 95%CI=1.005-2.002, p=0.047) 
models (Figure 4). No significant association be-
tween ABCB1-C3435T and breast cancer risk was 
observed in the Latinos subgroup (data not shown).
In overall meta-analysis, there was a high het-
erogeneity for T vs C (Pheterogeneity< 0.001; I
2=76%), 
TT vs CC (Pheterogeneity<0.001; I
2=68%), CT+TT vs CC 
(Pheterogeneity=0.012; I
2=53%), and TT vs CC+CT (Phet-
erogeneity=0.004; I
2=59%) models (Table 4). In Asian 
Figure 3. Forest plot for association of ABCB1-C3435T with breast cancer risk in Asian. A) T vs C model; B) TT vs 
CC model; C) CT+TT vs CC model; D) TT vs CC+CT model.
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studies, a high heterogeneity was found in T vs C 
(Pheterogeneity<0.001; I
2=79%) model (Table 4). Also, 
in Caucasian studies a true heterogeneity was 
found in T vs C (Pheterogeneity=0.017; I
2=64%), TT vs 
CC (Pheterogeneity=0.019; I
2=63%), CT vs CC (Phetero-
geneity=0.071; I
2=51%), and CT+TT vs CC (Pheterogene-
ity=0.025; I
2=61%) models (Table 4). In addition, in 
Latino studies a true heterogeneity was observed 
in T vs C (Pheterogeneity=0.077; I
2=68%), TT vs CC (Phet-
erogeneity=0.053; I
2=73%), and TT vs CT+CC (Pheterogene-
ity=0.074; I
2=69%).
The Egger’s test suggested a publication bias 
for the T vs C (PEgger=0.03), CT vs CC (PEgger=0.04), 
and CT+TT vs CC (PEgger=0.02) models in overall 
meta-analysis and for the T vs C (PEgg=0.01), TT vs 
CC (PEgger=0.01), CT+TT vs CC (PEgger=0.05), and TT 
vs CC+CT (PEgger=0.001) models in Caucasian me-
ta-analysis, whereas the shapes of funnel plot for 
all the 5 models in the Asian subgroup seemed 
approximately symmetrical (Figure 5). The distri-
bution of the studies on the funnel plot did not 
show any evidence of asymmetry, suggesting lack 
of publication bias. The lack of publication bias 
was confirmed by the Egger’s test (Table 4).
Sensitivity test was performed by excluding a 
study at one time and the results revealed that the 
estimates before and after the omission of each 
study were similar. These results suggested that 
this meta-analysis was stable (data not shown). 
Discussion
Breast cancer is the most common malignan-
cy in women in both developed and developing 
countries. This disease is a growing problem that 
affects about one in 8 women in their lifetime. The 
occurrence of breast cancer is on the increase (ap-
proximately 1% annually) [25-27] and the causes 
of this disease are poorly understood.  Risk factors 
such as age, geographical variation, family histo-
Figure 4. Forest plot for association of ABCB1-C3435T with breast cancer risk in Caucasian. A) T vs C model; B) 
TT vs CC model. 
Table 4. Results of heterogeneity and publication bias in the meta-analysis
Group
T vs C TT vs CC CT vs CC CT+TT vs CC TT vs CC+CT
Ph I2 Pe Ph I2 Pe Ph I2 Pe Ph I2 Pe Ph I2 Pe
Total < 0.001 76% 0.03 < 0.001 68% 0.11 0.110 34% 0.04 0.012 53% 0.02 0.004 59% 0.25
Asian < 0.001 79% 0.90 0.141 42% 0.38 0.235 28% 0.29 0.100 49% 0.31 0.459 0% 0.55
Cauca-
sian 0.017 64% 0.01 0.019 63% 0.01 0.071 51% 0.25 0.025 61% 0.05 0.222 28% 0.001
Ph: P heterogeneity (p< 0.1) was considered as a significant difference. Pe: P Egger (p< 0.05) was considered as a significant difference
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ry, lifestyle, and genetic factors play a key role in 
the genesis of this disease. Gene polymorphisms 
are increasingly considered as key risk factors for 
breast cancer occurrence in specific populations 
[28]. The identification of some key single nucle-
otide polymorphisms (SNP), which affect the ex-
pression and structure of proteins, could be help-
ful to predict susceptible individual for cancer 
risk [29].
ABCB1, as an ATP-dependent pump, can drive 
cytotoxic drugs and intracellular toxins out of 
the cell [30]. Since ABCB1 results in resistance to 
toxic xenobiotic and cytotoxic drugs, it is biolog-
ically possible that the C3434T transition might 
change the protective effects of the proteins [31]. 
Our case-control study revealed that there is a 
significant association of 3435T allele (OR=1.770, 
95%CI=1.236-2.535, p=0.002), 3435CT genotype 
(OR=1.661, 95% CI=1.017-2.713, p=0.042), and 34 
35TT genotype (OR=3.399, 95%CI=1.409-8.197, p= 
0.006) with breast cancer risk. Several studies have 
investigated the association of ABCB1-C3435T 
SNP and breast cancer risk with inconsistent 
results. For example Turgut et al. (2007) [5] and 
Tatari et al. (2009) [17] reported an association 
between ABCB1-3435T allele and breast cancer, 
whereas Henríquez-Hernández et al. (2009) [16] 
and Taheri et al. (2010) [19] didn’t find any asso-
ciation. Meta-analysis, as a powerful statistical 
tool, provides reconciliation of results by analyz-
ing pooled inconsistent data from several studies 
[32]. The present meta-analysis revealed that an 
association exists between ABCB1-C3435T poly-
morphism and breast cancer risk both in Asian 
and Caucasian studies. Also, our study revealed 
heterogeneity in the overall meta-analysis. After 
stratified meta-analysis, we didn’t find a true het-
erogeneity in the Asian subgroup. These might be 
ascribed to different environments, lifestyles, and 
genetic backgrounds among different ethnicities.
There are 4 meta-analyses over the ABCB1- 
C3435T gene polymorphism and breast cancer 
risk [31,33-35] which evaluate the association of 
ABCB1-C3435T and ABCB1-rs2214102 polymor-
phisms with breast cancer risk. Wang et al. (2012) 
[35] assessed the association of ABCB1-C3435T and 
overall risk of cancer and reported an association 
between C3435T polymorphism and increased risk 
of breast cancer. Also Sheng et al. (2012) [34] car-
ried out a meta-analysis between ABCB1-C3435T 
polymorphism and cancer risk. They also observed, 
with strong evidence, an association between AB-
CB1-C3435T and breast cancer risk. There was 
some incorrect data in previous studies which 
were corrected in the Wang et al. (2013) [31] study. 
Herein we report an updated meta-analysis with 
different ethnicity subgroups (Asian, Caucasian 
and Latinos).
Previous bioinformatic studies showed that 
SNPs may affect mRNA structure [36,37], protein 
function [38-40], and gene expression [41]. AB-
CB1-C3435T is a synonymous transition, there-
fore it has no effect on the function and structure 
of the protein, but it may affect the mRNA. SNPs 
Figure 5. Funnel plot for publication bias test in Asian meta-analysis. A) T vs C model; B) TT vs CC model; C) 
CT+TT vs CC model; D) TT vs CC+CT model.
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in gene leads to the formation of two different 
forms of mRNA. mRNA with different nucleotide 
at SNP location may vary in some features such 
as mRNA maturation, transport, degradation, and 
translation [42]. So it is fitting to employ in silico 
tools for evaluation of the deleterious effects of 
ABCB1-C3435T transition on the mRNA.
There are some limitations in our study that 
must be considered. For example, absence of origi-
nal data, such as age, drinking, smoking and family 
history might affect the precision of the association 
of ABCB1-C3435T and breast cancer. Also, this me-
ta-analysis lacks any data from African populations. 
In conclusion, the present meta-analysis sug-
gests that the ABCB1-C3435T polymorphism may 
be associated with breast cancer risk, however 
large sample size studies are required to confirm 
our results. To evaluate the precise results, stud-
ies with gene-environment and gene-gene inter-
actions are essential.
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